Recall of medicine. The FDA has said it thinks the potential carcinogens, known as nitrosamine impurities, are a result of the manufacturing processes the companies used. (Photo: Krisztian Bocsi/Bloomberg)

A third potential cancer-causing contaminant has been found in a widely used blood-pressure medicine, according to the U.S. Food and Drug Administration (FDA).

India-based generic-drug company Hetero Labs Ltd. discovered a chemical called NMBA in its version of losartan, the FDA said in a statement Friday. The contamination was found during heightened testing stirred by a far-reaching recall of generic blood-pressure drugs known as angiotensin II receptor blockers, or ARBs, that contain potential carcinogens NDMA and NDEA.

Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader

Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Commercial Lines
Commercial Lines
Compliance
Corporate Risk